Written by: Trey Brackin
Treatment-resistant depression is one of the most pressing challenges in behavioral health care. Up to 70 percent of people with major depression do not achieve remission with first-line medications, and roughly 30 percent develop treatment-resistant depression. Treatment-resistant depression is associated with higher mortality and suicide risk, as well as greater health care costs. Because depressive episodes can last nearly three times longer than in well-managed cases, the condition is linked to increased emergency department use, psychiatric hospitalization, homelessness, substance misuse, and long-term disability.
The burden is especially significant among veterans, who experience depression at higher rates than the civilian population, making treatment-resistant depression a major policy issue for the Department of Veterans Affairs. Against that backdrop, interest in the United States has grown around psychedelic-assisted therapies as potential alternatives or complements to traditional treatment approaches. Psilocybin, in particular, has drawn attention for its potential to disrupt rigid brain activity patterns associated with depression and may produce durable effects after limited dosing.
Emerging evidence suggests psilocybin and other psychedelic compounds, including ketamine, MDMA, and DMT, may offer meaningful clinical benefits for some patients with treatment-resistant depression. In one randomized controlled study, psilocybin performed as well as a leading SSRI for depression, and later clinical research has continued to support its promise, especially for patients with serious or life-limiting illnesses. While larger studies are still needed, the rapid onset of symptom relief seen in some trials makes psilocybin particularly noteworthy compared with conventional antidepressants, which often take weeks to work.
Psychedelic research has a long history, but restrictive drug policy in the second half of the 20th century sharply limited clinical use and scientific investigation by classifying many psychedelics as Schedule I substances. That regulatory environment, combined with public stigma, slowed research for decades. Other countries have moved more quickly than the United States in creating limited therapeutic pathways; for example, Germany and Australia have established regulatory pathways permitting limited therapeutic applications while continuing to expand clinical investigation.
Federal policy in the United States now appears to be shifting. Executive Order 14401, signed on April 18, 2026, directs HHS to allocate at least $50 million to support state-federal collaboration on psychedelic drug research and instructs HHS, FDA, and VA to coordinate on clinical trials, data sharing, and real-world evidence generation. The order also directs FDA and DEA to facilitate a pathway for eligible patients to access psychedelic drugs under the Right to Try Act and calls for timely rescheduling review where appropriate.
The VA has also deepened its role in this area. In July 2026, HHS and VA announced a partnership to improve coordination on psychedelic drug trials, workforce training, evidence-based clinical protocols, and real-world evidence generation for veterans’ mental health care. This collaboration is intended to help prepare the clinical infrastructure needed if additional psychedelic-assisted therapies receive FDA approval.
Regulatory uncertainty remains, however. MDMA-assisted therapy did not receive FDA approval, underscoring that future psychedelic therapies will still need to meet stringent evidentiary standards. At the same time, the FDA’s recent actions suggest continued interest in the field, including accelerated review mechanisms for psilocybin programs targeting treatment-resistant depression and major depressive disorder.
As policymakers and health care leaders evaluate these therapies, the conversation is increasingly shifting beyond efficacy alone to the broader system-level implications: potential cost savings, reduced acute care use, and less pressure on strained behavioral health systems.
